KNKenta Noda

Kenta Noda

*This is an algorithmically generated author record based on publicly available information.

Kenta Noda has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins

    by Makoto Niwa, Kenta Noda, Yoshiyuki Kobayashi, Itsuki Kageyama, Kota Kodama

    Using two diseases, Alzheimer's disease and muscular dystrophy as examples, in which many resources have been invested, trends in bioanalytical techniques for detection of peptide or protein biomarkers using mass spectrometry are reviewed using Web of Science database. Amyloid beta peptides have been used to detect Alzheimer's disease, and peptides obtained by tryptic digestion of dystrophin have been used to detect muscular dystrophy. Based on the recent interest in peripheral blood analysis, literature review was focused on biofluid analysis. Both electrospray or matrix-assisted laser desorption ionization mass spectrometry were employed for amyloid beta peptides, and high-resolution or ion mobility techniques had been introduced to enhance selectivity. Immunoprecipitation techniques were often used for pretreatment; however, emergence of combined use of different solid-phase extraction mode was observed. Regarding tryptic peptides obtained from dystrophin, there are few reported applications in biofluids, and typically electrospray ionization-selected reaction monitoring with pretreatment using solid-phase extraction were employed. Validity of blood biomarkers propelled development of bioanalytical methods by attracting research interest. The analytical methodologies was built on proven methods in the field of peptide analysis, and current interests were in techniques increasing selectivity and sensitivity, such as differential mobility spectrometry or parallel reaction monitoring.

  • Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial

    by Hisato Kawakami, Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Kenta Noda, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasuhiro Sakamoto, Ryohei Kawabata, et al.


  • Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19

    by Takehiro Hasegawa, Atsushi Nakagawa, Kohjin Suzuki, Kazuto Yamashita, Saya Yamashita, Niina Iwanaga, Eiya Tamada, Kenta Noda, Keisuke Tomii

    Coronavirus disease 2019 (COVID-19) is an acute respiratory disease; approximately 5% of patients developing severe COVID-19. It is known that cytokine release is associated with disease severity, but the relationship between the clinical phenotypes and inflammatory endotypes is not well understood. Therefore, we investigated the association between inflammatory biomarker-based endotypes and severe COVID-19 phenotypes. Interleukin (IL) -6, C-reactive protein (CRP), C–X–C motif chemokine (CXCL) 9, IL-18, C–C motif chemokine (CCL) 3, CCL17, IL-10, and related biomarkers were investigated in 57 COVID-19 patients, and their association with clinical characteristics was examined using a cluster analysis. Significantly higher blood levels of the eight inflammatory markers were noted in patients who developed acute respiratory distress syndrome (ARDS) than in those who did not develop ARDS (non-ARDS). Using a cluster analysis, the patient groups were classified into four clusters, of which two had patients with high IL-6 and CRP levels. In the cluster with high levels of Type 1 (T1) inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS, 65% of the patients developed acute kidney injury (AKI), and 78% of the patients developed pulmonary fibrosis. Furthermore, the levels of T1 inflammatory markers was already higher before ARDS development, than non-ARDS. In the cluster with high levels of T1 inflammatory markers, the patients frequently suffered from tissue damage, manifested as ARDS and AKI. Our findings identified distinct T1 inflammatory endotypes of COVID-19 and suggest the importance of monitoring T1 biomarkers for proactive treatment the severe complications.

  • Open Access

    Role of T1 Inflammatory Endotype in the Pathophysiology of Severe COVID-19

    by Takehiro Hasegawa, Astushi Nakagawa, Kohjin Suzuki, Kazuto Yamashita, Saya Yamashita, Niina Iwanaga, Eiya Tamada, Kenta Noda, Tomii Keisuke

    Background: Coronavirus disease (COVID-19) is a severe acute respiratory disease with approximately 5% of infected persons developing a serious disease. It is known that cytokine release is involved in its mechanism of aggravation, but the understanding of its inflammatory pathophysiology is not sufficiently advanced. Of specific importance to the development of therapeutic strategies is the understanding of its therapeutic endotype.Methods: Peripheral blood cytokines that were identified as being associated with COVID-19 in previous studies and eight inflammatory markers (IL-6, CRP, CXCL9, IL-18, CCL3, CCL17, IL-10, and VEGF) were measured in 57 COVID-19-infected individuals and their association with the patients’ condition was examined using a cluster analysis.Findings: The 8 inflammatory markers had significantly higher blood levels in patients who developed ARDS (ARDS) compared to those who did not develop ARDS during the observation period (non-ARDS). In the cluster analysis, the patient groups were classified into four clusters, of which two of the clusters had patients with high levels of IL-6 and CRP. In these clusters with high levels of IL-6 and CRP, in the clusters with high T1-inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS or pre-ARDS, and 65% of the patients developed AKI.Interpretation: In addition to IL-6 and CRP, which are reported as severity markers, clusters with high T1 inflammatory markers, the patients with high tissue damage have high ARDS and AKI frequency. The existence of different inflammatory endotypes was observed in the patient population with high IL-6 and CRP levels. This difference in inflammatory endotypes provides information essential for the development of therapeutic strategies for anti-inflammatory therapy. Funding: This research was funded by Sysmex Corporation.Declaration of Interests: TH, KS, KY, SY, NI, ET, and NK are employee of Sysmex corporation. TH, KS, and AN patent pending (patent for the biomarker). All other authors declare no competing interests. Ethics Approval Statement: The study complied with the requirements of the Declaration of Helsinki and was approved by the Medical Research Ethics Committee of Kobe City Medical Centre General Hospital and the Sysmex Cooperation. Informed consent was obtained from all of the patients using the following method: In compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects, the study information was published on the website and patients at the opportunity to withdraw their consent at any stage of the study. Therefore, the requirement for written informed consent from the enrolled patients was waived by the ethics committee.

  • Open Access

    Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma

    by Megumi Goto, Kenji Chamoto, Keiko Higuchi, Saya Yamashita, Kenta Noda, Takuya Iino, Masahiro Miura, Toshinari Yamasaki, Osamu Ogawa, Makoto Sonobe, et al.

    Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.


  • Open Access

    The utility of urinary CD80 as a diagnostic marker in patients with renal diseases

    by Shogo Minamikawa, Kandai Nozu, Shingo Maeta, Tomohiko Yamamura, Keita Nakanishi, Junya Fujimura, Tomoko Horinouchi, China Nagano, Nana Sakakibara, Hiroaki Nagase, et al.

    CD80, which regulates T cell activation, may provide a differential diagnostic marker between minimal change disease (MCD) and other renal diseases, including focal segmental glomerular sclerosis (FSGS). However, recent reports show contrasting results. Therefore, we evaluated the utility of urinary CD80 as a diagnostic biomarker. We collected 65 urine samples from 55 patients with MCD (n = 31), FSGS (n = 4), inherited nephrotic syndrome (n = 4), Alport syndrome (n = 5) and other glomerular diseases (n = 11), and control samples (n = 30). We measured urinary CD80 levels by ELISA. Urinary CD80 (ng/gCr) (median, interquartile range) levels were significantly higher in patients with MCD in relapse (91.5, 31.1–356.0), FSGS (376.2, 62.7–1916.0), and inherited nephrotic syndrome (220.1, 62.9–865.3), than in patients with MCD in remission (29.5, 21.7–52.8) (p < 0.05). Elevation of urinary CD80 was observed, even in patients with inherited nephrotic syndrome unrelated to T cell activation. Additionally, urinary CD80 was positively correlated with urinary protein levels. Our results suggest that urinary CD80 is unreliable as a differential diagnostic marker between MCD in relapse and FSGS or inherited kidney diseases. Increased urinary CD80 excretion was present in all patients with active kidney disease.


  • Open Access

    Immune‐complex level of cofilin‐1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer

    by Mamoru Satoh, Shigetsugu Takano, Kazuyuki Sogawa, Kenta Noda, Hideyuki Yoshitomi, Masumi Ishibashi, Kaoru Mogushi, Hirotaka Takizawa, Masayuki Otsuka, Hiroaki Shimizu, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. To improve its outcome, reliable biomarkers are urgently needed. In this study, we aimed to elucidate the key molecules involved in PDAC progression using proteomics approaches. First, we undertook 2‐D electrophoresis to identify the proteins overexpressed in PDAC tissues. Following the analysis of agarose gel spots, cofilin‐1 was identified and verified as a candidate protein commonly upregulated in PDAC tissues. In immunohistochemistry, cofilin‐1 was strongly expressed in the cytoplasm of PDAC cells. Samples were divided into two groups based on the level of cofilin‐1 expression. The high expression group showed significantly higher incidence of hematogenous dissemination in relapsed patients than the low expression group (P = 0.0083). In in vitro experiments, knockdown of cofilin‐1 significantly decreased chemotaxis in PDAC cell lines. After we confirmed that cofilin‐1 was secreted from PDAC cells, we established a detection system for the immune‐complex of cofilin‐1 in sera. Using this system, we measured the IC levels of cofilin‐1 in sera and observed that the IC levels of cofilin‐1 in PDAC patients were higher than those in healthy volunteers and patients with pancreatitis (PDAC vs. healthy volunteers, P < 0.0001; PDAC vs. patients with pancreatitis, P < 0.026). Notably, the IC levels of cofilin‐1 showed a stepwise increase during PDAC progression (P = 0.0034), and high IC levels of cofilin‐1 indicated poor prognosis of patients after surgery (P = 0.039). These results suggest that the IC of cofilin‐1 in sera is a potentially attractive serum biomarker for the prognosis of PDAC.


  • Open Access

    Sandwich ELISA Using a Mouse/Human Chimeric CSLEX-1 Antibody

    by J. Yamashita, I. Kobayashi, K. Tatematsu, H. Sezutsu, K. Noda, H. Ishihara

    BACKGROUND: An assay using a mouse antisialyl Lewis X (sLeX) antibody (CSLEX-1) is used clinically for screening and monitoring patients with breast cancer in Japan. However, the IgM isoform of CSLEX-1 is not preferred for the assay because the bulkiness of IgM generally causes poor accessibility to the antigen. To solve this problem, we developed an antisLeX mouse/human chimeric IgG antibody, CH-CSLEX-1, using transgenic silkworms. The performance of a homologous sandwich ELISA of CH-CSLEX1 was then evaluated. METHODS: To generate CH-CSLEX-1, we used a GAL4/UAS binary gene expression system in transgenic silkworms. The reactivities of CSLEX-1 and CH-CSLEX-1 were determined in a Biacore analysis. To confirm antigen specificity, 3 antigens [sLeX, sLeA, and Lewis Y (LeY)] were used. RESULTS: CH-CSLEX-1 formed correctly as an IgG class of immunoglobulin molecule with an isoelectric point close to the predicted value. The best combination for capturing and probing in a sandwich ELISA was determined as a homologous combination of CH-CSLEX-1. The CH-CSLEX-1 assay specifically detected sLeX, but not sLeA and LeY. A correlation analysis with 107 human samples showed good concordance between the conventional CSLEX-1 assay (homologous sandwich ELISA using CSLEX-1) and the CH-CSLEX-1 assay (r = 0.98). Moreover, the CH-CSLEX-1 assay was not affected by either human antimouse IgG antibodies (HAMA IgG) or HAMA IgM. CONCLUSIONS: The mouse/human chimeric antibody CH-CSLEX-1 allowed the establishment of a highly specific sandwich ELISA for sLeX that was not affected by HAMA.


  • Open Access

    Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9), a biomarker for various pathological conditions, is produced in post-blood collection by fibrinolysis and coagulation factors

    by Wataru Kikuchi, Motoi Nishimura, Takahisa Kuga, Sachio Tsuchida, Tatsuya Saito, Mamoru Satoh, Kenta Noda, Yoshio Kodera, Takeshi Tomonaga, Fumio Nomura

    Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum biomarker for chronic hepatitis that was discovered by proteomics analysis. Previous studies have shown that FIC5.9 is derived from the C-terminal region of fibrinogen alpha chain and the serum levels of FIC5.9 decrease in chronic hepatitis. It also have been reported that FIC5.9 cannot be detected in the blood stream of the systemic circulation and it is released from fibrinogen during blood clotting in collecting tube. However, the mechanism of FIC5.9 releasing from fibrinogen is unclear. We formulated a hypothesis that FIC5.9 is released by enzymes that are activated by post-blood collection and may be coagulation and fibrinolysis factors. In this study, we analyzed the mechanisms of FIC5.9 releasing from fibrinogen in healthy blood. Our analysis showed that thrombin acts as an initiator for FIC5.9 releasing, and that mainly plasmin cleaves N-terminal end of FIC5.9 and neutrophil elastase cleave C-terminal end of FIC5.9. FIC5.9 reflects minute changes in coagulation and fibrinolysis factors and may be associated with pathological conditions.